Corcept’s Coup De GRACE

The follow-on Cushing’s product relacorilant has hit in Phase III, and is forecast to lead the market – eventually.    

Red darts are placed in the center of the plate for darts and evening lights, a concept of targeting for business success.
• Source: Shutterstock

With sales of Korlym (mifepristone), the leading Cushing’s disease drug, forecast to start falling next year, Corcept Therapeutics Incorporated  needs a new money-spinner. Thanks to a hit in the pivotal GRACE trial, it appears to have one in relacorilant.

Key Takeaways
  • The GRACE trial of Corcept Therapeutics’ Cushing’s disease candidate relacorilant has succeeded in its pivotal trial.

Relacorilant, like its predecessor, aims to treat Cushing’s by modulating cortisol levels by competing with it at the glucocorticoid receptor....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

More from R&D

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.